Literature DB >> 7762557

Molecular analysis of the acid sphingomyelinase deficiency in a family with an intermediate form of Niemann-Pick disease.

K Ferlinz1, R Hurwitz, M Weiler, K Suzuki, K Sandhoff, M T Vanier.   

Abstract

A novel point mutation in the lysosomal acid sphingomyelinase gene has been identified in the recently reported Serbian family with a clinically and biochemically atypical intermediate form of Niemann-Pick disease. The mutation was a T1171-->G transversion resulting in substitution of glycine for normal tryptophan at amino acid residue 391. The coding sequence was otherwise normal. All of the five affected individuals were almost certainly homoallelic, and both of the two obligate heterozygotes studied also carried the same mutation. This mutation is therefore likely to be directly associated with the atypical phenotype of these patients. Expression in COS-1 cells suggested a higher residual activity than that in cultured fibroblasts. A recently developed high-affinity rabbit antihuman sphingomyelinase antibody allowed us to study for the first time the biosynthesis, processing, and targeting of a mutant sphingomyelinase by metabolic labeling of cultured fibroblasts. The mutant enzyme protein was normally synthesized, processed, and routed to the lysosome but was apparently unstable and degraded rapidly once it reached the lysosome. Together with the finding of the relatively high residual activity in COS-1 cells, we interpret our observations to mean that instability and rapid breakdown of the mature mutant enzyme protein, due to the mutation rather than direct inactivation of the catalytic activity, is the primary mechanism for the deficiency of sphingomyelinase activity in these patients. A high prevalence of this mutation in the Serbian population is likely, since the family pedigree indicates that members from four reportedly unrelated families must have contributed the same mutation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762557      PMCID: PMC1801117     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  19 in total

1.  The cerebral defect in Tay-Sachs disease and Niemann-Pick disease.

Authors:  A C CROCKER
Journal:  J Neurochem       Date:  1961-04       Impact factor: 5.372

2.  Identification of a missense mutation (S436R) in the acid sphingomyelinase gene from a Japanese patient with type B Niemann-Pick disease.

Authors:  T Takahashi; R J Desnick; G Takada; E H Schuchman
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

3.  Biochemical studies in Niemann-Pick disease. III. In vitro and in vivo assays of sphingomyelin degradation in cultured skin fibroblasts and amniotic fluid cells for the diagnosis of the various forms of the disease.

Authors:  M T Vanier; R Rousson; I Garcia; G Bailloud; M C Juge; A Revol; P Louisot
Journal:  Clin Genet       Date:  1985-01       Impact factor: 4.438

4.  Processing of human acid sphingomyelinase in normal and I-cell fibroblasts.

Authors:  R Hurwitz; K Ferlinz; G Vielhaber; H Moczall; K Sandhoff
Journal:  J Biol Chem       Date:  1994-02-18       Impact factor: 5.157

5.  Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures.

Authors:  S Albouz; J J Hauw; Y Berwald-Netter; J M Boutry; R Bourdon; N Baumann
Journal:  Biomedicine       Date:  1981-12

6.  Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors.

Authors:  R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

7.  Identification and expression of five mutations in the human acid sphingomyelinase gene causing types A and B Niemann-Pick disease. Molecular evidence for genetic heterogeneity in the neuronopathic and non-neuronopathic forms.

Authors:  T Takahashi; M Suchi; R J Desnick; G Takada; E H Schuchman
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

8.  A family with visceral course of Niemann-Pick disease, macular halo syndrome and low sphingomyelin degradation rate.

Authors:  W Sperl; G Bart; M T Vanier; H Christomanou; I Baldissera; E Steichen-Gersdorf; E Paschke
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

9.  The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts.

Authors:  R Hurwitz; K Ferlinz; K Sandhoff
Journal:  Biol Chem Hoppe Seyler       Date:  1994-07

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  7 in total

1.  Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant.

Authors:  U Schepers; G Glombitza; T Lemm; A Hoffmann; A Chabas; P Ozand; K Sandhoff
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 2.  Lysosomal lipid storage diseases.

Authors:  Heike Schulze; Konrad Sandhoff
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

3.  A model of the acid sphingomyelinase phosphoesterase domain based on its remote structural homolog purple acid phosphatase.

Authors:  Marian Seto; Marc Whitlow; Margaret A McCarrick; Subha Srinivasan; Ying Zhu; Rene Pagila; Robert Mintzer; David Light; Anthony Johns; Janet A Meurer-Ogden
Journal:  Protein Sci       Date:  2004-12       Impact factor: 6.725

Review 4.  The Contribution of Lysosomes to DNA Replication.

Authors:  Joanna Maria Merchut-Maya; Apolinar Maya-Mendoza
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

Review 5.  My journey into the world of sphingolipids and sphingolipidoses.

Authors:  Konrad Sandhoff
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

6.  Functional implications of novel human acid sphingomyelinase splice variants.

Authors:  Cosima Rhein; Philipp Tripal; Angela Seebahn; Alice Konrad; Marcel Kramer; Christine Nagel; Jonas Kemper; Jens Bode; Christiane Mühle; Erich Gulbins; Martin Reichel; Cord-Michael Becker; Johannes Kornhuber
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

7.  Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids.

Authors:  Marta Moskot; Joanna Jakóbkiewicz-Banecka; Elwira Smolińska; Bogdan Banecki; Grzegorz Węgrzyn; Magdalena Gabig-Cimińska
Journal:  Metab Brain Dis       Date:  2015-07-26       Impact factor: 3.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.